Drugs for ADHD — MCQs
Which drug for ADHD has a risk of growth retardation in children?
According to DSM 5 criteria, all are true about ADHD except:
A 19-year-old man working as a driver comes to Psychiatrist with excessive anxiety and fear. He reports that every time he drives over a bump in the road, he is convinced that he has accidentally run over a small child. He has to pull over and check underneath his car for blood and retrace his driving route to look for any injured children. As a result, he is always late for work. He also has intrusive thoughts about stabbing his coworkers. He prays to try to erase these thoughts from his mind, but this rarely helps. First-line pharmacological treatment of this patient's condition primarily affects which of the following neurotransmitters?
A 30-year-old male presents with a history of consuming an unknown substance. On examination, the patient has diaphoresis, headache, and features resembling acute coronary spasm. Which of the following clinical features is least likely to be present in this patient?
Atomoxetine is used in the management of which of the following conditions?
Stimulant drugs are primarily given to children for the treatment of:
All are used in attention deficit hyperactivity disorder (ADHD) except:
The cardiovascular side effects of Dexmedetomidine are as follows:
Ocular effects that include mydriasis are characteristic of which of the following drugs?
Which of the following antidepressants is least likely to have sexual side effects?
Drugs for ADHD Indian Medical PG Practice Questions and MCQs
Question 1: Which drug for ADHD has a risk of growth retardation in children?
- A. Methylphenidate (Correct Answer)
- B. Modafinil
- C. Clonidine
- D. Atomoxetine
Explanation: ***Methylphenidate*** - **Methylphenidate** (a stimulant) can cause a **transient reduction in growth velocity** due to effects on appetite suppression and potentially growth hormone secretion [1]. - While this reduction is often temporary and catch-up growth typically occurs, it is a **well-documented and clinically significant risk** requiring growth monitoring in children [1, 2]. - Among ADHD medications, stimulants like methylphenidate have the **most pronounced effect on growth** [1].*Modafinil* - **Modafinil** is primarily used for narcolepsy and other sleep disorders, not a first-line treatment for ADHD. - It works through different mechanisms than traditional stimulants and is not typically associated with growth retardation in the ADHD population.*Clonidine* - **Clonidine** is an alpha-2 adrenergic agonist used to treat ADHD, particularly for hyperactivity, impulsivity, and sleep problems. - It does **not have a known risk of growth retardation** in children.*Atomoxetine* - **Atomoxetine** is a non-stimulant medication for ADHD that works by selectively inhibiting norepinephrine reuptake. - While atomoxetine can also affect growth velocity in some children (FDA labeling includes growth monitoring recommendations), the effect is **generally less pronounced than with stimulants like methylphenidate**. - Methylphenidate remains the **most recognized** for this adverse effect among ADHD medications.
Question 2: According to DSM 5 criteria, all are true about ADHD except:
- A. For diagnoses, symptoms should be present before 7 years (Correct Answer)
- B. Adult ADHD symptoms are similar to children
- C. Symptoms should be present in more than one setting
- D. For diagnoses, symptoms should be present before 12 years
Explanation: ***For diagnoses, symptoms should be present before 7 years*** - This statement is **INCORRECT** according to DSM-5 criteria - DSM-IV required symptoms before **7 years of age**, but DSM-5 **revised** this requirement - DSM-5 now requires symptoms to be present before **12 years of age** - This is the **correct answer** for this EXCEPT question as it is the false statement *Adult ADHD symptoms are similar to children* - This statement is generally TRUE - Core symptoms of **inattention, hyperactivity, and impulsivity** persist into adulthood - However, manifestations change: hyperactivity in adults often presents as **restlessness** or internal feeling of being "on edge" rather than overt physical activity - The similarity in core symptoms makes this statement true *Symptoms should be present in more than one setting* - This statement is TRUE per DSM-5 criteria - Symptoms must be present in **two or more settings** (e.g., home, school, work, with friends) - This criterion ensures symptoms reflect a **pervasive pattern** rather than situational behavior - This is a key requirement for ADHD diagnosis *For diagnoses, symptoms should be present before 12 years* - This statement is TRUE and reflects current DSM-5 criteria - Several **inattentive or hyperactive-impulsive symptoms** must be present before **12 years of age** - This updated age criterion (changed from 7 in DSM-IV) allows for later recognition of symptoms - This helps differentiate ADHD from conditions with adult onset
Question 3: A 19-year-old man working as a driver comes to Psychiatrist with excessive anxiety and fear. He reports that every time he drives over a bump in the road, he is convinced that he has accidentally run over a small child. He has to pull over and check underneath his car for blood and retrace his driving route to look for any injured children. As a result, he is always late for work. He also has intrusive thoughts about stabbing his coworkers. He prays to try to erase these thoughts from his mind, but this rarely helps. First-line pharmacological treatment of this patient's condition primarily affects which of the following neurotransmitters?
- A. Dopamine
- B. Serotonin (Correct Answer)
- C. Norepinephrine
- D. Acetylcholine
Explanation: ***Serotonin*** - The described symptoms (obsessive thoughts about harming others, compulsive checking, and attempts to neutralize thoughts with prayer) are highly characteristic of **Obsessive-Compulsive Disorder (OCD)**. - **Selective Serotonin Reuptake Inhibitors (SSRIs)** are the first-line pharmacological treatment for OCD, and they work by increasing the availability of serotonin in the synaptic cleft. *Dopamine* - Dopamine dysregulation is primarily implicated in disorders such as **schizophrenia** and **Parkinson's disease**, and to some extent in ADHD and addiction. - While dopamine may play a role in some aspects of OCD, typical first-line treatments do not primarily target dopamine. *Norepinephrine* - Norepinephrine is largely involved in the **fight-or-flight response**, attention, and arousal, and is a target for treating depression and anxiety disorders with SNRIs. - While some antidepressants that affect norepinephrine may be used if SSRIs are ineffective, they are not considered the primary neurotransmitter target for first-line OCD treatment. *Acetylcholine* - Acetylcholine is crucial for **muscle contraction**, learning, and memory, and imbalances are associated with conditions like **Alzheimer's disease** and myasthenia gravis. - It is not a primary target for the pharmacological treatment of OCD.
Question 4: A 30-year-old male presents with a history of consuming an unknown substance. On examination, the patient has diaphoresis, headache, and features resembling acute coronary spasm. Which of the following clinical features is least likely to be present in this patient?
- A. Hypertension
- B. Tachycardia
- C. Hyperthermia
- D. Bradycardia (Correct Answer)
- E. Mydriasis
Explanation: ***Bradycardia*** - The presented symptoms of diaphoresis, headache, and coronary spasm are consistent with **stimulant intoxication** (e.g., cocaine, amphetamines). - Stimulants typically cause **tachycardia** due to sympathetic overactivity, making bradycardia the least likely finding. *Hypertension* - **Stimulant intoxication** leads to increased sympathetic activity, causing **vasoconstriction** and elevated blood pressure. - This is a common and expected finding in cases presenting with coronary spasm due to substance abuse. *Tachycardia* - **Sympathetic overstimulation** from an unknown substance, particularly stimulants, directly increases heart rate. - This symptom closely aligns with the patient's presentation of diaphoresis and coronary spasm. *Hyperthermia* - Elevated body temperature is a frequent consequence of **stimulant overdose** due to increased metabolic activity and impaired thermoregulation. - **Diaphoresis** (sweating) can be a compensatory mechanism for hyperthermia or a direct effect of sympathetic activation. *Mydriasis* - **Pupillary dilation** is a characteristic finding in sympathomimetic toxidrome caused by stimulant drugs. - This occurs due to alpha-adrenergic stimulation of the radial muscle of the iris and is commonly seen with cocaine or amphetamine use.
Question 5: Atomoxetine is used in the management of which of the following conditions?
- A. Bipolar disorder
- B. Schizophrenia
- C. Depression
- D. ADHD (Correct Answer)
Explanation: ***Correct: ADHD*** * **Atomoxetine** is a **selective norepinephrine reuptake inhibitor (SNRI)** primarily used in the management of **Attention-Deficit/Hyperactivity Disorder (ADHD)**. * It is a **non-stimulant** medication, making it a suitable alternative for patients who do not respond to or cannot tolerate traditional stimulant medications for ADHD. * FDA-approved in 2002, atomoxetine remains an important treatment option, particularly for patients with concerns about stimulant abuse potential or those with comorbid anxiety disorders. *Incorrect: Bipolar disorder* * **Bipolar disorder** is typically treated with mood stabilizers (e.g., lithium, valproate), antipsychotics, and sometimes antidepressants, but atomoxetine is not a first-line or common treatment option. * While some ADHD symptoms can overlap with bipolar disorder, atomoxetine is specifically designed for ADHD and lacks the broad mood-stabilizing effects needed for bipolar disorder. *Incorrect: Schizophrenia* * **Schizophrenia** is a severe mental disorder treated primarily with **antipsychotic medications** that target dopamine and serotonin systems. * Atomoxetine does not have efficacy in treating the positive or negative symptoms of schizophrenia and is not indicated for this condition. *Incorrect: Depression* * While atomoxetine affects **norepinephrine**, some SNRIs (e.g., venlafaxine, duloxetine) are used for depression. However, atomoxetine's primary indication and efficacy profile are not for treating **major depressive disorder**. * Its mechanism of action is more specifically tailored to the neurochemical imbalances seen in ADHD rather than the broader neurotransmitter dysregulation in depression.
Question 6: Stimulant drugs are primarily given to children for the treatment of:
- A. Speech developmental disorder
- B. Conduct disorder
- C. ADHD (Correct Answer)
- D. Pervasive disorder
Explanation: ***ADHD*** - Stimulant medications like **methylphenidate** and **amphetamine** are first-line treatments for attention-deficit/hyperactivity disorder (ADHD) in children. - They work by increasing the levels of **dopamine** and **norepinephrine** in the brain, improving focus and reducing impulsivity. *Speech developmental disorder* - This disorder primarily involves difficulties with **language production** or comprehension. - Treatment typically focuses on **speech therapy** and educational interventions, not stimulant medications. *Conduct disorder* - This condition involves persistent patterns of **antisocial behavior**, aggression, and violations of rules. - While therapy is the primary treatment, if there are co-occurring symptoms of ADHD, stimulants might be used to address those specific symptoms, but aren't a direct treatment for conduct disorder itself. *Pervasive disorder* - This term is an older term for what is now known as **autism spectrum disorder (ASD)**. - There is no evidence that stimulant medications are effective for the core symptoms of ASD, and they might exacerbate some behavioral symptoms.
Question 7: All are used in attention deficit hyperactivity disorder (ADHD) except:
- A. Dextro-amphetamine
- B. Methylphenidate
- C. Phenobarbitone (Correct Answer)
- D. Atomoxetine
Explanation: ***Phenobarbitone*** - **Phenobarbitone** (phenobarbital) is a **barbiturate** primarily used as an **anticonvulsant** and for sedation. - It works as a **CNS depressant** and would worsen, not improve, symptoms of ADHD, which include inattention, hyperactivity, and impulsivity. - **Not indicated** for ADHD management and may cause sedation, cognitive impairment, and paradoxical hyperactivity in children. *Dextro-amphetamine* - **Dextro-amphetamine** is a **stimulant medication** commonly used in ADHD. - It works by increasing levels of **dopamine** and **norepinephrine** in the brain, improving focus and reducing hyperactivity. - Approved for ADHD treatment in both children and adults. *Methylphenidate* - **Methylphenidate** is a **stimulant** widely prescribed for ADHD and considered a first-line treatment. - It acts as a **norepinephrine-dopamine reuptake inhibitor**, thereby increasing the availability of these neurotransmitters. - Available in immediate-release and extended-release formulations. *Atomoxetine* - **Atomoxetine** is a **non-stimulant** selective norepinephrine reuptake inhibitor (SNRI) used for ADHD. - It is particularly useful in patients who cannot tolerate stimulants or have comorbid anxiety disorders. - Preferred when there is concern about substance abuse or tic disorders.
Question 8: The cardiovascular side effects of Dexmedetomidine are as follows:
- A. Hypertension and Tachycardia
- B. Hypertension and Bradycardia
- C. Hypotension and Bradycardia (Correct Answer)
- D. Hypotension and Tachycardia
Explanation: ***Hypotension and Bradycardia*** - **Dexmedetomidine** is an **alpha-2 adrenergic agonist** that causes a dose-dependent decrease in heart rate (bradycardia) and blood pressure (hypotension) due to reduced sympathetic outflow. - The initial hypertensive effect seen with rapid IV administration is usually transient and followed by sustained hypotension. *Hypertension and Tachycardia* - This combination is not typical for **dexmedetomidine**, which primarily exerts its effects by centrally reducing sympathetic tone, leading to lowered heart rate and blood pressure. - **Tachycardia** is a rare and usually reflex-mediated response if severe hypotension occurs, but it's not a primary effect. *Hypertension and Bradycardia* - While an initial, transient **hypertension** can occur with rapid **dexmedetomidine** infusion due to peripheral alpha-2 stimulation, this is not its predominant long-term cardiovascular effect. - The sustained effect is usually **hypotension**, not hypertension, making this option incorrect as a primary side effect. *Hypotension and Tachycardia* - Although **hypotension** is a common side effect of **dexmedetomidine**, **tachycardia** is generally not. - The drug mainly causes a reduction in heart rate (**bradycardia**) as part of its central sympatholytic action.
Question 9: Ocular effects that include mydriasis are characteristic of which of the following drugs?
- A. phenylephrine (alpha agonist) (Correct Answer)
- B. neostigmine (cholinesterase inhibitor)
- C. phentolamine (alpha blocker)
- D. mecamylamine (ganglionic blocker)
Explanation: ***phenylephrine (alpha agonist)*** - **Phenylephrine** is a direct-acting **alpha-1 adrenergic agonist** that causes contraction of the **pupillary dilator muscle**, leading to **mydriasis** (pupil dilation). [1] - It is frequently used clinically to dilate pupils for **ophthalmologic examinations** due to its selective action on alpha-1 receptors in the eye. [2] *neostigmine (cholinesterase inhibitor)* - **Neostigmine** inhibits acetylcholinesterase, increasing acetylcholine at the neuromuscular junction and muscarinic receptors. This leads to **miosis** (pupil constriction), not mydriasis. - Its ophthalmic use is primarily for treating **glaucoma** by improving aqueous humor outflow through cholinergic effects on the ciliary muscle. *phentolamine (alpha blocker)* - **Phentolamine** is a **non-selective alpha-adrenergic antagonist** that blocks both alpha-1 and alpha-2 receptors. - Alpha-1 receptor blockade in the eye would relax the pupillary dilator muscle, leading to **miosis** or prevention of mydriasis, not its induction. *mecamylamine (ganglionic blocker)* - **Mecamylamine** is a **ganglionic blocker** that antagonizes nicotinic receptors in both sympathetic and parasympathetic ganglia. - Blocking parasympathetic ganglia can cause some mydriasis, but ganglionic blockers have widespread, non-selective autonomic effects and are not primarily used for isolated mydriasis.
Question 10: Which of the following antidepressants is least likely to have sexual side effects?
- A. Amitriptyline
- B. Fluoxetine
- C. Venlafaxine
- D. Mirtazapine (Correct Answer)
Explanation: ***Mirtazapine*** - **Mirtazapine** is an atypical antidepressant (NaSSA - Noradrenergic and Specific Serotonergic Antidepressant) that works by blocking alpha-2 adrenergic receptors, enhancing serotonin and norepinephrine release [1]. - It has the **lowest incidence of sexual side effects** among antidepressants because it blocks 5-HT2 and 5-HT3 receptors while avoiding significant 5-HT1A stimulation, which is responsible for sexual dysfunction with SSRIs [1]. - It may even **improve libido** in some cases due to its unique receptor profile and histamine antagonism that can enhance sleep quality. *Amitriptyline* - **Amitriptyline** is a tricyclic antidepressant (TCA) with broad receptor actions, including anticholinergic and antihistaminic effects. - TCAs like amitriptyline can cause **sexual dysfunction** (including erectile dysfunction and decreased libido) due to their anticholinergic properties and effects on multiple neurotransmitter systems, though typically less severe than SSRIs. *Fluoxetine* - **Fluoxetine** is a selective serotonin reuptake inhibitor (SSRI), and while effective for depression, it is associated with a **high incidence of sexual side effects** (30-70% of patients) [2]. - These side effects include **decreased libido**, **anorgasmia**, and **erectile dysfunction**, caused by increased serotonergic activity at 5-HT2 receptors in areas regulating sexual function [2]. *Venlafaxine* - **Venlafaxine** is a serotonin-norepinephrine reuptake inhibitor (SNRI), increasing both serotonin and norepinephrine levels in the brain [1]. - Like SSRIs, SNRIs such as venlafaxine frequently cause **sexual dysfunction**, with common complaints including reduced libido and difficulty achieving orgasm due to enhanced serotonergic neurotransmission [1].
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free